Ipca Labs profit after tax declines 26 percent to Rs 199.9 crore in Q3
New Delhi: Ipca Laboratories Ltd on Monday reported a 26 per cent decline in consolidated profit after tax to Rs 199.96 crore in the third quarter ended December 31, 2021.The company had posted a consolidated net profit of Rs 265.47 crore in the corresponding period last fiscal, Ipca Laboratories said in a regulatory filing.Consolidated revenue from operations during October-December 2021...
New Delhi: Ipca Laboratories Ltd on Monday reported a 26 per cent decline in consolidated profit after tax to Rs 199.96 crore in the third quarter ended December 31, 2021.
The company had posted a consolidated net profit of Rs 265.47 crore in the corresponding period last fiscal, Ipca Laboratories said in a regulatory filing.
Consolidated revenue from operations during October-December 2021 stood at Rs 1,430.47 crore as against Rs 1,409.83 crore in the year-ago quarter, it added.
Total expenses during the quarter were higher at Rs 1,182.74 crore, compared with Rs 1,098.71 crore a year ago. Cost of materials consumed stood at Rs 417.04 crore, up from Rs 393.51 crore in the same period last fiscal, the company said.
Read also: IPCA Labs invests Rs 25 crore In ABCD Technologies
"Overall, total formulations' revenue stood at Rs 992.77 crore in the third quarter as compared to Rs 954.34 crore in the year-ago period, up four per cent," reports PTI.
The domestic formulations segment's revenue grew 23 per cent in the third quarter to Rs 645.27 crore as compared with Rs 523.16 crore a year ago, the company said.
However, the active pharmaceutical ingredients (APIs) segment witnessed a 12 per cent decline in revenue at Rs 309.38 crore as against Rs 352.07 crore in the year-ago quarter, it added.
Read also: ICPA introduces 'Wet Mouth' - Saliva Substitute For Individuals Suffering From Dry Mouth
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India. The company was founded by K.B. Mehla, Dr. N.S. Tibrawala in 1949. The company is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.
It has 15 APIs & 11 Formulations manufacturing facility across the globe. IPCA labs has leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy in India.
Read also: Ipca Labs buys 13.09 percent stake in Trophic Wellness for Rs 21.20 crore
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd